专利检索 cpc:"A61K38/191" 第 1 页

1.

发明公开
USE OF NOX INHIBITORS FOR TREATMENT OF CANCER 审中-公开

公开(公告)号：US20240358687A1

公开(公告)日：2024-10-31

申请号：US18651929

申请日：2024-05-01

申请人： CALLIDITAS THERAPEUTICS SUISSE SA , UNIVERSITY OF SOUTHAMPTON

发明人： Philippe WIESEL , Freddy HEITZ , Gareth THOMAS , Christopher HANLEY , Kristy FORD

IPC分类号： A61K31/437 , A61K31/4025 , A61K31/5377 , A61K35/17 , A61K38/19 , A61K39/00 , A61K39/245 , A61K39/395 , A61P35/00

CPC分类号： A61K31/437 , A61K31/4025 , A61K31/5377 , A61K35/17 , A61K38/191 , A61K39/245 , A61K39/3955 , A61P35/00 , A61K2039/505 , A61K2039/507

摘要： The present invention is related to compounds, methods, compositions and uses that are able to restore responsiveness to immunotherapy, in particular immune check point inhibitors or anti-cancer vaccine or to anti-angiogenesis treatment.

2.

发明公开
METHODS FOR PREVENTING AND TREATING CHRONIC PAIN 审中-公开

公开(公告)号：US20240299448A1

公开(公告)日：2024-09-12

申请号：US18181865

申请日：2023-03-10

申请人： Luda DIATCHENKO , Jeffrey MOGIL , Lucas Vasconcelos LIMA , Marc PARISIEN , Massimo ALLEGRI , Nader GHASEMLOU , Mohamad KARAKY

发明人： Luda DIATCHENKO , Jeffrey MOGIL , Lucas Vasconcelos LIMA , Marc PARISIEN , Massimo ALLEGRI , Nader GHASEMLOU , Mohamad KARAKY

IPC分类号： A61K35/15 , A61K31/197 , A61K31/485 , A61K31/56 , A61K38/18 , A61K38/19 , A61K38/20 , A61K38/21 , A61P25/04

CPC分类号： A61K35/15 , A61K31/197 , A61K31/485 , A61K31/56 , A61K38/1866 , A61K38/191 , A61K38/2006 , A61K38/204 , A61K38/2053 , A61K38/208 , A61K38/21 , A61P25/04

摘要： The present invention relates to a method of preventing or treating chronic pain comprising administering to a subject, in an amount/number effective to elicit, sustain or potentiate an inflammatory process, a pro-inflammatory compound, myeloid leukocyte cells or a substance that increases the number or activity of myeloid leukocyte cells.

3.

发明授权
TRAILshort antibody and methods of use 有权

公开(公告)号：US12084508B2

公开(公告)日：2024-09-10

申请号：US17410832

申请日：2021-08-24

申请人： Mayo Foundation for Medical Education and Research

发明人： Andrew D. Badley

IPC分类号： A61K39/395 , C07K16/28 , A61K38/19

CPC分类号： C07K16/2875 , A61K39/39558 , C07K16/2878 , A61K38/191 , C07K2317/24 , C07K2317/73 , C07K2317/75 , C07K2317/76

摘要： This document provides antibodies against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) short, and more particularly to humanized TRAILshort antibodies that can neutralize TRAILshort. For example, materials and methods for using one or more humanized TRAILshort antibodies to induce apoptosis (e.g., via TRAIL mediated cell death, natural killer (NK) cytotoxicity, and/or CD8+ T cell killing) are provided.

4.

发明授权
Engineered CD46-specific effector cells and uses thereof in the treatment of cancer 有权

公开(公告)号：US12049511B2

公开(公告)日：2024-07-30

申请号：US16349258

申请日：2017-11-10

申请人： FORTIS THERAPEUTICS, INC.

发明人： Marc Nasoff , Joshua Park

IPC分类号： C07K16/28 , A61K35/17 , A61K38/17 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/00 , A61K39/395 , A61P35/00 , C07K14/705 , C07K14/725 , C07K19/00 , C12N5/0783 , C12N15/63 , A61K9/00 , A61K31/675 , A61K31/7076 , A61K45/06

CPC分类号： C07K16/2896 , A61K35/17 , A61K38/177 , A61K38/1774 , A61K38/191 , A61K38/20 , A61K38/2013 , A61K38/2046 , A61K38/208 , A61K38/2086 , A61K38/217 , A61K39/001112 , A61K39/001129 , A61K39/3955 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K19/00 , C12N5/0638 , C12N5/0646 , C12N15/63 , A61K9/0019 , A61K9/0029 , A61K31/675 , A61K31/7076 , A61K2039/5156 , A61K2039/5158 , A61K2039/54 , A61K2039/545 , A61K2039/572 , A61K2039/884 , A61K45/06 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N2510/00

摘要： Engineered effector cells, such as chimeric antigen receptors (CARs), are used for enhanced immunogenic response to specific antigen, such as CD46. Disclosed herein are compositions and methods of treatment a cancer overexpressing CD46, which comprises a pharmaceutical composition comprising an engineered effector cell.

5.

发明授权
RANKL-specific agent for treating metastatic disease 有权

公开(公告)号：US12048744B2

公开(公告)日：2024-07-30

申请号：US17024425

申请日：2020-09-17

申请人： Probiocon GmbH

发明人： Helmut Salih , Ludger Grosse-Hovest , Andreas Herrmann , Hans-Georg Kopp , Stefanie Maurer

IPC分类号： A61K39/00 , A61K38/19 , A61K39/395 , C07K14/705 , C07K16/28 , C12Q1/68 , G01N33/50 , G01N33/574

CPC分类号： A61K39/395 , A61K38/19 , A61K38/191 , C07K14/705 , C07K14/70578 , C07K16/2875 , C12Q1/68 , G01N33/5011 , G01N33/574 , C07K2317/21 , C07K2317/76 , C07K2319/30 , G01N2333/70575

摘要： The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.

6.

发明授权
Bioactive peptides and methods of use thereof 有权

公开(公告)号：US12048734B2

公开(公告)日：2024-07-30

申请号：US17233141

申请日：2021-04-16

申请人： OP-T LLC

发明人： David H. Wagner, Jr. , Gisela M. Vaitaitis , Charles W. Henry , Martin G. Yussman

IPC分类号： A61K38/17 , A61K38/08 , A61K38/10 , A61K38/19 , A61K47/60 , A61K47/68 , A61P31/14 , A61P37/06

CPC分类号： A61K38/191 , A61K47/60 , A61K47/6811 , A61P31/14 , A61P37/06

摘要： Methods and compositions are disclosed for treating and preventing cytokine release syndrome (CRS), acute respiratory distress syndrome (CRS), and alveolar capillary injury (ACI) in a subject.

7.

发明授权
Use of NOX inhibitors for treatment of cancer 有权

公开(公告)号：US12011436B2

公开(公告)日：2024-06-18

申请号：US16760910

申请日：2018-11-01

申请人： CALLIDITAS THERAPEUTICS SUISSE SA , UNIVERSITY OF SOUTHAMPTON

发明人： Philippe Wiesel , Freddy Heitz , Gareth Thomas , Christopher Hanley , Kirsty Ford

IPC分类号： A61K31/437 , A61K31/4025 , A61K31/5377 , A61K35/17 , A61K38/19 , A61K39/00 , A61K39/245 , A61K39/395 , A61P35/00

CPC分类号： A61K31/437 , A61K31/4025 , A61K31/5377 , A61K35/17 , A61K38/191 , A61K39/245 , A61K39/3955 , A61P35/00 , A61K2039/505 , A61K2039/507

摘要： The present invention is related to compounds, methods, compositions and uses that are able to restore responsiveness to immunotherapy, in particular immune check point inhibitors or anti-cancer vaccine or to anti-angiogenesis treatment.

8.

发明公开
Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses Thereof 审中-公开

公开(公告)号：US20240101961A1

公开(公告)日：2024-03-28

申请号：US18521129

申请日：2023-11-28

申请人： Mesoblast, Inc.

发明人： Stan Gronthos , Andrew Christopher William Zannettino

IPC分类号： C12N5/0775 , A61K35/28 , A61K38/18 , A61K38/19 , A61K38/20 , A61L27/38 , C12N5/0735

CPC分类号： C12N5/0663 , A61K35/28 , A61K38/1858 , A61K38/1875 , A61K38/191 , A61K38/195 , A61K38/2006 , A61L27/3804 , A61L27/3834 , A61L27/3839 , A61L27/3886 , A61L27/3895 , C12N5/0606 , C12N5/0662 , C12N5/0664 , C12N5/0665 , C12N5/0666 , C12N5/0667 , C12N5/0668 , C12N2510/00

摘要： The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.

9.

发明公开
METHODS OF TREATING CANCER USING TIGIT-AND LIGHT-BASED CHIMERIC PROTEINS 审中-公开

公开(公告)号：US20240016892A1

公开(公告)日：2024-01-18

申请号：US18265048

申请日：2021-12-03

申请人： Shattuck Labs, Inc.

发明人： Taylor SCHREIBER , George FROMM , Suresh DE SILVA

IPC分类号： A61K38/17 , A61K38/19 , A61K49/00 , A61P35/00 , G01N33/574 , C12Q1/6886

CPC分类号： A61K38/1774 , A61K38/191 , A61K49/0004 , A61P35/00 , G01N33/57484 , C12Q1/6886 , C07K2319/30 , C12Q2600/106 , A61B10/0045

摘要： The present disclosure relates, inter alia, to compositions and methods, including chimeric proteins that find use in the treatment of disease, and to detection and treatment of drug resistant cancer using chimeric proteins.